Zyprexa: Advanced Antipsychotic Treatment for Schizophrenia and Bipolar Disorder
Zyprexa
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.03 | $91.00 (0%) | 🛒 Add to cart |
| 60 | $2.22 | $182.00 $133.00 (27%) | 🛒 Add to cart |
| 90 | $1.96 | $273.00 $176.00 (36%) | 🛒 Add to cart |
| 120 | $1.82 | $364.00 $218.00 (40%) | 🛒 Add to cart |
| 180 | $1.68
Best per pill | $546.00 $303.00 (45%) | 🛒 Add to cart |
| Product dosage: 2.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.46 | $41.00 (0%) | 🛒 Add to cart |
| 120 | $0.40 | $54.67 $48.00 (12%) | 🛒 Add to cart |
| 180 | $0.35 | $82.00 $63.00 (23%) | 🛒 Add to cart |
| 270 | $0.31 | $123.00 $85.00 (31%) | 🛒 Add to cart |
| 360 | $0.30
Best per pill | $164.00 $108.00 (34%) | 🛒 Add to cart |
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.57 | $107.00 (0%) | 🛒 Add to cart |
| 60 | $2.62 | $214.00 $157.00 (27%) | 🛒 Add to cart |
| 90 | $2.31 | $321.00 $208.00 (35%) | 🛒 Add to cart |
| 120 | $2.15 | $428.00 $258.00 (40%) | 🛒 Add to cart |
| 180 | $1.99
Best per pill | $642.00 $358.00 (44%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.88 | $53.00 (0%) | 🛒 Add to cart |
| 90 | $0.80 | $79.50 $72.00 (9%) | 🛒 Add to cart |
| 120 | $0.76 | $106.00 $91.00 (14%) | 🛒 Add to cart |
| 180 | $0.72 | $159.00 $130.00 (18%) | 🛒 Add to cart |
| 270 | $0.70 | $238.50 $188.00 (21%) | 🛒 Add to cart |
| 360 | $0.68
Best per pill | $318.00 $246.00 (23%) | 🛒 Add to cart |
| Product dosage: 7.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.07 | $62.00 $62.00 (0%) | 🛒 Add to cart |
| 60 | $1.63 | $124.00 $98.00 (21%) | 🛒 Add to cart |
| 90 | $1.49 | $186.00 $134.00 (28%) | 🛒 Add to cart |
| 120 | $1.42 | $248.00 $170.00 (31%) | 🛒 Add to cart |
| 180 | $1.34 | $372.00 $241.00 (35%) | 🛒 Add to cart |
| 270 | $1.29
Best per pill | $558.00 $349.00 (37%) | 🛒 Add to cart |
Synonyms | |||
Similar products
Zyprexa (olanzapine) is an atypical antipsychotic medication specifically engineered to target both positive and negative symptoms of schizophrenia and acute manic or mixed episodes associated with bipolar I disorder. Developed through rigorous clinical research, it functions as a multi-receptor antagonist with particular affinity for serotonin, dopamine, muscarinic, histamine, and adrenergic receptors. This comprehensive mechanism provides a robust therapeutic profile for managing severe psychiatric conditions, offering both rapid symptom control and sustained maintenance therapy. Approved by the FDA and other major regulatory bodies worldwide, Zyprexa represents a cornerstone in modern psychopharmacology for treatment-resistant cases and complex neuropsychiatric presentations.
Features
- Active ingredient: Olanzapine
- Available formulations: Oral tablets (2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg), orally disintegrating tablets (Zyprexa Zydis), and intramuscular injection for acute agitation
- Pharmacologic class: Thienobenzodiazepine derivative
- Half-life: 21–54 hours (permitting once-daily dosing)
- Metabolism: Hepatic, primarily via CYP1A2 and CYP2D6 isoenzymes
- Bioavailability: Approximately 60% when administered orally
- Protein binding: 93% bound to plasma proteins
Benefits
- Demonstrates significant efficacy in reducing both positive symptoms (hallucinations, delusions) and negative symptoms (social withdrawal, apathy) in schizophrenia
- Provides rapid stabilization of acute manic and mixed episodes in bipolar I disorder within 7–10 days of initiation
- Offers flexible dosing options including fast-dissolving formulations for patients with swallowing difficulties or non-adherence concerns
- Shows superior efficacy compared to conventional antipsychotics in treatment-resistant schizophrenia cases
- Maintains long-term symptom control with once-daily dosing support
- Reduces hospitalization rates and improves overall quality of life metrics
Common use
Zyprexa is primarily indicated for the treatment of schizophrenia in adults and adolescents aged 13–17 years, and for acute manic or mixed episodes associated with bipolar I disorder in adults and pediatric patients aged 13–17 years. It is also approved for maintenance monotherapy in bipolar I disorder. Off-label uses include treatment of behavioral disturbances in dementia (with caution), treatment-resistant depression (as augmentation therapy), and management of chemotherapy-induced nausea and vomiting. Clinical decision-making should always prioritize FDA-approved indications unless substantial evidence supports alternative applications.
Dosage and direction
Schizophrenia (Adults): Initiate at 5–10 mg once daily, adjust by 5 mg increments at intervals of at least 1 week. Target range: 10–15 mg daily. Maximum: 20 mg/day.
Schizophrenia (Adolescents 13–17): Start at 2.5–5 mg once daily, titrate to target dose of 10 mg/day. Maximum: 20 mg/day.
Bipolar I Mania (Adults): Initiate at 10–15 mg once daily, adjust based on response. Maintenance: 5–20 mg daily.
Bipolar I Mania (Adolescents 13–17): Start at 2.5–5 mg once daily, titrate to 10 mg/day.
Elderly/Debilitated: Consider lower starting dose (2.5 mg/day).
Administer without regard to meals. For Zyprexa Zydis: place tablet on tongue, allow disintegration, swallow with or without water. Intramuscular formulation: 2.5–10 mg dose, may repeat every 2–4 hours (max 30 mg/24h).
Precautions
- Metabolic monitoring essential: baseline and periodic weight, BMI, waist circumference, blood glucose, lipid profile
- Orthostatic hypotension monitoring recommended, particularly during initial dose titration
- Regular assessment for extrapyramidal symptoms and tardive dyskinesia
- Caution in patients with cardiovascular disease, cerebrovascular disease, or conditions predisposing to hypotension
- Monitor for signs of neuroleptic malignant syndrome (NMS)
- Assess for falls risk, especially in elderly patients
- Periodic liver function tests recommended
- Consider reduced dosing in smokers due to CYP1A2 induction
Contraindications
- Known hypersensitivity to olanzapine or any component of the formulation
- Patients with narrow-angle glaucoma
- Concurrent use with other drugs that significantly prolong QTc interval
- Severe hepatic impairment (Child-Pugh Class C)
- Combination with fluvoxamine (strong CYP1A2 inhibitor) without dose adjustment
Possible side effect
Very common (>10%): Somnolence, weight gain, increased appetite, dizziness, orthostatic hypotension
Common (1–10%): Peripheral edema, elevated prolactin, extrapyramidal symptoms, dry mouth, constipation, dyspepsia, elevated liver enzymes, akathisia
Uncommon (0.1–1%): QTc prolongation, leukopenia, neutropenia, rash, photosensitivity
Rare (<0.1%): Neuroleptic malignant syndrome, tardive dyskinesia, pancreatitis, diabetic ketoacidosis, seizures
Elderly patients with dementia-related psychosis: Increased risk of cerebrovascular adverse events and mortality
Drug interaction
- Strong CYP1A2 inhibitors (fluvoxamine): Increase olanzapine exposure approximately 2–3 fold—reduce Zyprexa dose by 50%
- CYP1A2 inducers (carbamazepine, omeprazole, smoking): Decrease olanzapine exposure—may require dose adjustment
- Antihypertensive agents: Enhanced hypotensive effects
- Benzodiazepines: Potential for additive sedation and respiratory depression
- Dopamine agonists: Antagonistic effects may reduce efficacy
- Alcohol: Enhanced cognitive and motor impairment
- Medications that prolong QTc interval: Additive risk of torsades de pointes
Missed dose
If a dose is missed, administer as soon as remembered unless approaching time for next scheduled dose. Do not double dose to make up for missed administration. Maintain regular dosing schedule. For patients using Zyprexa Zydis, ensure proper storage conditions if dose is significantly delayed.
Overdose
Symptoms: Drowsiness, slurred speech, tachycardia, hypotension, extrapyramidal symptoms, agitation, coma. Fatalities have occurred in combination with other drugs.
Management: Immediate medical supervision required. Provide supportive care including gastric lavage if presented early. Administer activated charcoal. Monitor cardiac function continuously. Hemodialysis not effective due to high protein binding. No specific antidote available.
Storage
Store at controlled room temperature (20–25°C/68–77°F). Excursions permitted to 15–30°C (59–86°F). Keep in original container, tightly closed. Protect from light and moisture. For Zyprexa Zydis: maintain in original blister package until administration. Keep all medications out of reach of children and pets.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Prescription and use of Zyprexa must be supervised by a qualified healthcare professional. Individual response to medication may vary. Always follow the prescribed dosage and report any adverse effects to your physician immediately. Not all possible interactions or side effects are listed here.
Reviews
Clinical Evidence: Multiple randomized controlled trials demonstrate Zyprexa’s superiority over placebo in both schizophrenia and bipolar mania, with effect sizes of 0.5–0.8 on standardized rating scales. Long-term studies show maintained efficacy for up to 2 years with appropriate monitoring.
Expert Consensus: Treatment guidelines from APA and WFSBP position Zyprexa as a first-line option for acute mania and treatment-resistant schizophrenia, while noting the need for proactive metabolic management.
Patient-reported Outcomes: Surveys indicate improved quality of life measures particularly in social functioning and cognitive performance, though weight gain remains a significant concern requiring ongoing management.